Zheng Qi-Qi, Lin Wen-Feng
Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang Province, P.R. China.
Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Nanbaixiang, Ouhai District, Wenzhou City, Wenzhou City, 325000, Zhejiang Province, P.R. China.
BMC Cancer. 2025 Apr 14;25(1):680. doi: 10.1186/s12885-025-13759-z.
This study aimed to investigate the effect of miR-325 on KIF20B expression and its role in the invasion and proliferation of colorectal cancer cells.
Colorectal cancer HCT116 cells were cultured and transfected with a miR-325 inhibitor. KIF20B expression was assessed using quantitative polymerase chain reaction (qPCR) and western blotting. Cell proliferation was assessed with the Cell Counting Kit-8 (CCK8) assay, while invasion was evaluated using Transwell and scratch wound healing assays. The expression levels of the invasion-related proteins Matrix Metalloproteinase-2 (MMP-2) and MMP-9 were also analyzed.
The q-PCR and western blot results demonstrated that KIF20B expression was significantly reduced by miR-325 inhibition. The CCK8 assay revealed that miR-325 inhibition decreased cell proliferation. Furthermore, Transwell and Scratch Wound Healing assays showed that miR-325 inhibition suppressed the invasive capacity of colorectal cancer cells. The inhibition of miR-325 also led to decreased expression levels of MMP-2 and MMP-9.
miR-325 inhibition effectively suppresses KIF20B expression, reducing the invasion and proliferation of colorectal cancer cells, suggesting miR-325 as a potential therapeutic target.
本研究旨在探讨miR-325对KIF20B表达的影响及其在结肠癌细胞侵袭和增殖中的作用。
培养结肠癌细胞HCT116并转染miR-325抑制剂。采用定量聚合酶链反应(qPCR)和蛋白质印迹法评估KIF20B的表达。使用细胞计数试剂盒-8(CCK8)检测法评估细胞增殖,同时使用Transwell和划痕伤口愈合检测法评估细胞侵袭。还分析了侵袭相关蛋白基质金属蛋白酶-2(MMP-2)和MMP-9的表达水平。
q-PCR和蛋白质印迹结果表明,抑制miR-325可显著降低KIF20B的表达。CCK8检测显示,抑制miR-325可降低细胞增殖。此外,Transwell和划痕伤口愈合检测表明,抑制miR-325可抑制结肠癌细胞的侵袭能力。抑制miR-325还导致MMP-2和MMP-9的表达水平降低。
抑制miR-325可有效抑制KIF20B表达,降低结肠癌细胞的侵袭和增殖,提示miR-325作为潜在的治疗靶点。